Impax Confirms Patent Challenge Relating to RENAGEL Tablets, 400 mg and 800 mg

Mar 17, 2009 - Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Genzyme Corporation in connection with its RENAGEL (sevelamer hydrochloride) tablets, 400 mg and 800 mg.

The details can be read here.